Denali Therapeutics, Inc. (DNLI)
22.29
+0.86
(+4.01%)
USD |
NASDAQ |
Feb 25, 16:00
22.43
+0.14
(+0.63%)
Pre-Market: 09:21
Denali Therapeutics Research and Development Expense (Quarterly) : 101.95M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Protalix Biotherapeutics, Inc. | 4.467M |
| Enovis Corp. | 29.74M |
| Masimo Corp. | 30.50M |
| Twist Bioscience Corp. | 17.13M |
| Agenus, Inc. | 23.60M |